Business Context and Reporting Period
Company: Lucid Diagnostics Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: October 28, 2021
Reporting Period: Single event date (October 28, 2021)
Business Context: The filing discloses a regulatory and corporate development regarding the company's primary product, the EsoGuard® Esophageal DNA Test.
Key Financial Metrics
This Form 8-K is a disclosure of a specific event and does not contain financial statements. The filing text does not provide values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
Award Recognition: On October 28, 2021, Lucid Diagnostics announced that its EsoGuard® Esophageal DNA Test was selected as the winner of the "Diagnostics Innovation of the Year" award. This award was part of the inaugural awards program conducted by BioTech Breakthrough.
Guidance, Outlook, and Risks
Management Commentary: The filing references a press release (Exhibit 99.1) detailing the award but does not include forward-looking guidance, financial outlook, or specific risk factors within the body of this report.
Legal Status: The information furnished under Item 7.01 is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and is not incorporated by reference into other disclosure documents unless expressly stated.
Investor Verification Checklist
- Verify the full text of the press release (Exhibit 99.1) for details on the award criteria and potential market impact.
- Confirm the company's current financial status via the most recent 10-Q or 10-K, as this 8-K contains no financial data.
- Monitor subsequent filings for any commercialization updates related to the EsoGuard® test following this recognition.